Norepinephrine News and Research

RSS

Combination of two stress hormones shuts down brain activity for goal-directed behaviour

Cognition psychologists at the Ruhr-Universit-t together with colleagues from the University Hospital Bergmannsheil (Prof. Dr. Martin Tegenthoff) have discovered why stressed persons are more likely to lapse back into habits than to behave goal-directed. The team of PD Dr. Lars Schwabe and Prof. Dr. Oliver Wolf from the Institute for Cognitive Neuroscience have mimicked a stress situation in the body using drugs.

26 Jul 2012

Rapamycin enhances learning and memory in young mice

Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with a drug that has Polynesian roots.

30 Jun 2012

Millennium introduces novel pharmacogenetic testing

Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing.

29 Jun 2012

Social-class discrimination can contribute to physiologic changes associated with poorer health

Discrimination felt by teenagers based on their social class background can contribute to physiologic changes associated with poorer health, according to a new study led by a University of Wisconsin-Madison researcher.

16 Jun 2012

Too much salt and aldosterone leads to high blood pressure, tissue damage

Nearly 40 percent of the small adrenal tumors that cause big problems with high blood pressure share a genetic mutation that causes patients to retain too much sodium, researchers report.

31 May 2012

Critically ill patients on antidepressants more likely to die

Researchers at Beth Israel Deaconess Medical Center, in Boston, and the Massachusetts Institute of Technology in Cambridge, have found that critically ill patients were more likely to die if they were taking the most commonly prescribed antidepressants when they were admitted to the intensive care unit (ICU).

23 May 2012

PharMEDium to present enhanced labeling for ICU services at NTI and Critical Care Expo

Amy Langan, Vice President of Marketing and Business Development, announced that PharMEDium will highlight its enhanced labeling for sterile intravenous compounded ICU Services at the National Teaching Institute (NTI) and Critical Care Exposition, May 19-24, 2012 in Orlando, Florida.

19 May 2012

Beta blockers do not reduce risk of colorectal cancer

A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that even long-term use or subtypes of beta blockers showed no reduction of colorectal cancer risk.

14 May 2012

PET imaging for sudden cardiac arrest can identify candidates for ICDs

New research from the University at Buffalo suggests that cardiologists may have a new way to identify patients who are at the highest risk of sudden cardiac arrest, and the most likely to benefit from receiving an implantable cardiac defibrillator (ICD).

11 May 2012

Two studies suggest long-term value of Deplin in treating MDD

Two studies presented this week at the 164th Annual Meeting of the American Psychiatric Association suggest the long-term value of Deplin (L-methylfolate 15mg) in treating major depressive disorder (MDD) and describe subsets of patients who may benefit more robustly from this medical food.

9 May 2012

Everett Labs announces availability of Pregnitude for women with fertility problems

A new non-prescription Reproductive Support Dietary Supplement, Pregnitude, which contains myo-inositol (2 g), plus folic acid (200 mcg), is now available for women who are having difficulty conceiving, Everett Laboratories announced today. In clinical studies, Pregnitude has been shown to help support ovulation function and menstrual cycle regularity as well as support the quality of a woman's eggs.

8 May 2012

ACE inhibitors or ARBs could treat and prevent PTSD

Traumatized people who take a class of common blood pressure medications tend to have less severe post-traumatic stress symptoms, researchers have found.

2 May 2012

UVA engineer and biologist named recipients of Hartwell Individual Biomedical Research Awards

University of Virginia engineer Silvia Salinas Blemker and biologist Christopher Deppmann have been named recipients of 2011 Hartwell Individual Biomedical Research Awards, which provide $100,000 in annual research support for three years to each awardee.

16 Apr 2012

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Apr 2012

Fear of flying can be cured independently of YOH or after 4 sessions of VRET

This randomized controlled trial shows that fear of flying can be cured independently of drug condition [yohimbine hydrochloride (a noradrenaline agonist) or placebo] after 4 sessions of virtual reality exposure therapy (VRET).

15 Mar 2012

Prazosin drug shows promise against PTSD-related nightmares

Mayo Clinic researchers this week will announce the use of the blood pressure drug prazosin as an effective treatment to curb post- traumatic stress disorder (PTSD)-related nightmares.

6 Mar 2012

Converted umbilical cord stem cells hold hope for spinal cord injuries, multiple sclerosis

For the first time ever, stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for spinal cord injuries and multiple sclerosis, among other nervous system diseases.

18 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Positive link between physical activity and academic performance of children

A systematic review of previous studies suggests that there may be a positive relationship between physical activity and the academic performance of children, according to a report in the January issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Jan 2012

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype - homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.

31 Dec 2011